727 related articles for article (PubMed ID: 30650326)
1. Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Llanos-Cuentas A; Lacerda MVG; Hien TT; Vélez ID; Namaik-Larp C; Chu CS; Villegas MF; Val F; Monteiro WM; Brito MAM; Costa MRF; Chuquiyauri R; Casapía M; Nguyen CH; Aruachan S; Papwijitsil R; Nosten FH; Bancone G; Angus B; Duparc S; Craig G; Rousell VM; Jones SW; Hardaker E; Clover DD; Kendall L; Mohamed K; Koh GCKW; Wilches VM; Breton JJ; Green JA
N Engl J Med; 2019 Jan; 380(3):229-241. PubMed ID: 30650326
[TBL] [Abstract][Full Text] [Related]
2. Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
Lacerda MVG; Llanos-Cuentas A; Krudsood S; Lon C; Saunders DL; Mohammed R; Yilma D; Batista Pereira D; Espino FEJ; Mia RZ; Chuquiyauri R; Val F; Casapía M; Monteiro WM; Brito MAM; Costa MRF; Buathong N; Noedl H; Diro E; Getie S; Wubie KM; Abdissa A; Zeynudin A; Abebe C; Tada MS; Brand F; Beck HP; Angus B; Duparc S; Kleim JP; Kellam LM; Rousell VM; Jones SW; Hardaker E; Mohamed K; Clover DD; Fletcher K; Breton JJ; Ugwuegbulam CO; Green JA; Koh GCKW
N Engl J Med; 2019 Jan; 380(3):215-228. PubMed ID: 30650322
[TBL] [Abstract][Full Text] [Related]
3. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
Llanos-Cuentas A; Lacerda MV; Rueangweerayut R; Krudsood S; Gupta SK; Kochar SK; Arthur P; Chuenchom N; Möhrle JJ; Duparc S; Ugwuegbulam C; Kleim JP; Carter N; Green JA; Kellam L
Lancet; 2014 Mar; 383(9922):1049-58. PubMed ID: 24360369
[TBL] [Abstract][Full Text] [Related]
4. Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
Rodrigo C; Rajapakse S; Fernando D
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD010458. PubMed ID: 32892362
[TBL] [Abstract][Full Text] [Related]
5. Operational effectiveness of tafenoquine and primaquine for the prevention of Plasmodium vivax recurrence in Brazil: a retrospective observational study.
Brito M; Rufatto R; Brito-Sousa JD; Murta F; Sampaio V; Balieiro P; Baía-Silva D; Castro V; Alves B; Alencar A; Duparc S; Grewal Daumerie P; Borghini-Fuhrer I; Jambert E; Peterka C; Edilson Lima F; Carvalho Maia L; Lucena Cruz C; Maciele B; Vasconcelos M; Machado M; Augusto Figueira E; Alcirley Balieiro A; Batista Pereira D; Lacerda M
Lancet Infect Dis; 2024 Jun; 24(6):629-638. PubMed ID: 38452779
[TBL] [Abstract][Full Text] [Related]
6. Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
Rajapakse S; Rodrigo C; Fernando SD
Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD010458. PubMed ID: 25921416
[TBL] [Abstract][Full Text] [Related]
7. Optimal balance of benefit versus risk for tafenoquine in the treatment of Plasmodium vivax malaria.
Sharma R; Sharma H; Jones S; Borghini-Fuhrer I; Domingo GJ; Gibson RA; Rolfe K; Tan L; Fiţa IG; Chen C; Bird P; Pingle A; Duparc S
Malar J; 2024 May; 23(1):145. PubMed ID: 38741094
[TBL] [Abstract][Full Text] [Related]
8. Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax.
Milligan R; Daher A; Villanueva G; Bergman H; Graves PM
Cochrane Database Syst Rev; 2020 Aug; 8():CD012656. PubMed ID: 32816320
[TBL] [Abstract][Full Text] [Related]
9. Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study.
Sutanto I; Soebandrio A; Ekawati LL; Chand K; Noviyanti R; Satyagraha AW; Subekti D; Santy YW; Crenna-Darusallam C; Instiaty I; Budiman W; Prasetya CB; Lardo S; Elyazar I; Duparc S; Cedar E; Rolfe K; Fernando D; Berni A; Jones S; Kleim JP; Fletcher K; Sharma H; Martin A; Taylor M; Goyal N; Green JA; Tan LK; Baird JK
Lancet Infect Dis; 2023 Oct; 23(10):1153-1163. PubMed ID: 37236221
[TBL] [Abstract][Full Text] [Related]
10. Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial.
Taylor WRJ; Thriemer K; von Seidlein L; Yuentrakul P; Assawariyathipat T; Assefa A; Auburn S; Chand K; Chau NH; Cheah PY; Dong LT; Dhorda M; Degaga TS; Devine A; Ekawati LL; Fahmi F; Hailu A; Hasanzai MA; Hien TT; Khu H; Ley B; Lubell Y; Marfurt J; Mohammad H; Moore KA; Naddim MN; Pasaribu AP; Pasaribu S; Promnarate C; Rahim AG; Sirithiranont P; Solomon H; Sudoyo H; Sutanto I; Thanh NV; Tuyet-Trinh NT; Waithira N; Woyessa A; Yamin FY; Dondorp A; Simpson JA; Baird JK; White NJ; Day NP; Price RN
Lancet; 2019 Sep; 394(10202):929-938. PubMed ID: 31327563
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.
Walsh DS; Wilairatana P; Tang DB; Heppner DG; Brewer TG; Krudsood S; Silachamroon U; Phumratanaprapin W; Siriyanonda D; Looareesuwan S
Clin Infect Dis; 2004 Oct; 39(8):1095-103. PubMed ID: 15486831
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Analysis of Sex-Stratified
Devine A; Howes RE; Price DJ; Moore KA; Ley B; Simpson JA; Dittrich S; Price RN
Am J Trop Med Hyg; 2020 Jul; 103(1):394-403. PubMed ID: 32372747
[TBL] [Abstract][Full Text] [Related]
13. Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure.
Warrasak S; Euswas A; Fukuda MM; Ittiverakul M; Miller RS; Krudsood S; Ohrt C
Int Ophthalmol; 2019 Aug; 39(8):1767-1782. PubMed ID: 30269312
[TBL] [Abstract][Full Text] [Related]
14. Operational feasibility of Plasmodium vivax radical cure with tafenoquine or primaquine following point-of-care, quantitative glucose-6-phosphate dehydrogenase testing in the Brazilian Amazon: a real-life retrospective analysis.
Brito M; Rufatto R; Murta F; Sampaio V; Balieiro P; Baía-Silva D; Castro V; Alves B; Alencar A; Duparc S; Grewal Daumerie P; Borghini-Fuhrer I; Jambert E; Peterka C; Edilson Lima F; Carvalho Maia L; Lucena Cruz C; Maciele B; Vasconcelos M; Machado M; Augusto Figueira E; Alcirley Balieiro A; Menezes A; Ataídes R; Batista Pereira D; Lacerda M
Lancet Glob Health; 2024 Mar; 12(3):e467-e477. PubMed ID: 38365417
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria.
Fukuda MM; Krudsood S; Mohamed K; Green JA; Warrasak S; Noedl H; Euswas A; Ittiverakul M; Buathong N; Sriwichai S; Miller RS; Ohrt C
PLoS One; 2017; 12(11):e0187376. PubMed ID: 29121061
[TBL] [Abstract][Full Text] [Related]
16. Single dose tafenoquine for preventing relapse in people with plasmodium vivax malaria-an updated meta-analysis.
Anjum MU; Naveed AK; Mahmood SN; Naveed OK
Travel Med Infect Dis; 2020; 36():101576. PubMed ID: 32036012
[TBL] [Abstract][Full Text] [Related]
17. Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping.
Beck HP; Wampfler R; Carter N; Koh G; Osorio L; Rueangweerayut R; Krudsood S; Lacerda MV; Llanos-Cuentas A; Duparc S; Rubio JP; Green JA
J Infect Dis; 2016 Mar; 213(5):794-9. PubMed ID: 26500351
[TBL] [Abstract][Full Text] [Related]
18. Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial.
Vélez ID; Hien TT; Green JA; Martin A; Sharma H; Rousell VM; Breton JJ; Ernest TB; Rolfe K; Taylor M; Mohamed K; Jones SW; Chau NH; Hoa NT; Duparc S; Tan LK; Goyal N
Lancet Child Adolesc Health; 2022 Feb; 6(2):86-95. PubMed ID: 34871570
[TBL] [Abstract][Full Text] [Related]
19. Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (
Rueangweerayut R; Bancone G; Harrell EJ; Beelen AP; Kongpatanakul S; Möhrle JJ; Rousell V; Mohamed K; Qureshi A; Narayan S; Yubon N; Miller A; Nosten FH; Luzzatto L; Duparc S; Kleim JP; Green JA
Am J Trop Med Hyg; 2017 Sep; 97(3):702-711. PubMed ID: 28749773
[TBL] [Abstract][Full Text] [Related]
20. Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria.
Watson J; Taylor WRJ; Bancone G; Chu CS; Jittamala P; White NJ
PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006440. PubMed ID: 29677199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
